Neviah Genomics

Company Overview

Snapshot

Founded in November 2012, Neviah Genomics operates with 11–50 employees. The company achieved a key development milestone for its PropheTox™ bioassay in January 2015, focusing on the early prediction of drug-induced liver toxicity.

Business overview

Neviah Genomics specializes in health technology and life sciences, developing PropheTox, a drug toxicity screening service. This technology utilizes mathematical analysis of cell behavior and machine learning, combined with prior biological knowledge, to detect low-dose, chronic toxic effects. The company's innovative assay design and optimized decision support algorithms are applied to expression data from experiments involving primary liver cells exposed to various compounds, serving the pharmaceutical and laboratory sectors.

Strategic signal

In January 2015, Neviah Genomics announced a key development milestone for its PropheTox™ bioassay, designed for the early prediction of drug-induced liver toxicity. This advancement signals progress in the company's core technology, potentially enhancing drug development safety and efficiency within the pharmaceutical industry.

Company Intelligence Q&A

What is Neviah Genomics' primary focus?

Neviah Genomics focuses on the early detection of drug-induced toxicity through its PropheTox screening service, utilizing advanced bioassay technology.

When was Neviah Genomics founded?

Neviah Genomics was founded in November 2012.

What is PropheTox?

PropheTox is Neviah Genomics' drug toxicity screening service that uses mathematical analysis of cell behavior, machine learning, and biological knowledge to predict drug-induced liver toxicity.

What was a significant development for Neviah Genomics in early 2015?

In January 2015, Neviah Genomics achieved a key development milestone for its PropheTox™ bioassay, specifically for the early prediction of drug-induced liver toxicity.